Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen plus ALXN2220 versus eplontersen plus placebo in adults with ATTR-CM
2025-523908-75-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of clobazam and cliramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in CPET peak VO2. Started Jul 2026; status: completed.
02
Drugs
clobazamcliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2025-523908-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523908-75-00.